血清MiR-1825在前列腺癌患者中的研究

Study on serum MiR-1825 in patients with prostate cancer

目的探讨血清MiR-1825在前列腺癌(PCa)中的意义。方法选择2015年7月至2016年9月本科室收治的确诊PCa患者72例,健康对照组3 4例。采用免疫印迹法和荧光定量聚合酶链反应(RT-PCR)检测,应用t或秩和检验对两组实验结果进行分析。结果两组的MiR-1825值比较,差异有统计学意义(P<0.0 5);而在前列腺癌患者中,TNM分期(高级别、低级别)、同一患者治疗前后MiR-1825值比较,差异均存在统计学意义(P<0.05);而不同Gleason评分、有无骨转移、激素抵抗或依赖比较,MiR-1825值差异均无统计学意义(P>0.05)。通过ROC曲线分析显示,MiR-1825的特异性为91.2%,敏感性为93.1%。结论MiR-1825对肿瘤的诊断、恶性分级、评估患者治疗效果有临床指导意义。

Objective To investigate the serum levels of MiR-1825 in prostate cancer(PCa) and its significance. Methods From July 2015 to September 2016, a total of 72 PCa patients and 34 cases of healthy control group were detected and analyzed by Western blot and fluorescence quantitative polymerase chain reaction (RT-PCR). Results PCa group compared with healthy control group, there was statistically significant in MiR-1825 index ( P < 0. 05). In the PCa group, TNM grouping (high level, low level), and same patient before and after treatment grouping,MiR-1825 was statistically significant ( P < 0. 05). The Gleason score group, bone metastasis group and grade hormone resistance group were not statistically significant. Sensitivity and specificity were analyzed by ROC curve, MiR-1825 specificity(91. 2%), sensitivity(93.1%). Conclusions According to our findings, MiR-1825 is of clinical significance in the diagnosis, malignancy, and evaluation of therapeutic efficacy.